At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate Low Doses of the MTP-Inhibitor AEGR-733 on Hepatic Fat Accumulation as Measured by Magnetic Resonance Spectroscopy
In Brief
A Phase 2 clinical trial evaluating AEGR-733, placebo, and 3 other interventions for Hyperlipidemia. Completed, enrolled 260 participants across 15 sites.
Detailed Summary
To determine safety and effectiveness of low-dose therapeutic AEGR-733 +/- atorvastatin, ezetimibe or fenofibrate (compared to placebo) on liver fat accumulation measured by Magnetic Resonance Spectroscopy
Study Details
Timeline
Interventions
3 capsules each evening for each 4-week period
3 capsules each evening for each 4-week period
3 capsules each evening for each 4-week period
3 capsules each evening for each 4-week period
3 capsules each evening for each 4-week period
3 capsules each evening for each 4-week period
3 capsules each evening for each 4-week period
3 capsules each evening for each 4-week period